Qingkesha^® Posaconazole Injection is a new-generation triazole antifungal drug, widely used in the prevention and treatment of invasive fungal diseases. It primarily works by inhibiting CYP450-dependent 14α-demethylase, which subsequently blocks the synthesis of ergosterol, leading to a disruption in the biosynthesis of the fungal cell membrane and altered cell membrane permeability, thereby inhibiting fungal growth. Qingkesha^® Posaconazole Injection was approved for market in July 2023 as a Class 4 chemical drug and is listed as a Category B product under the national medical insurance program. Compared to other triazole drugs, Posaconazole has a broad antifungal spectrum, high tissue concentration, unique pharmacokinetics, good safety profile, and fewer drug interactions, making it the first-line drug recommended in both domestic and international guidelines for the prevention and treatment of invasive fungal diseases.